Anixa Biosciences, Inc.
NASDAQ•ANIX
CEO: Dr. Amit Kumar Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1983-10-07
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Contact Information
Market Cap
$99.47M
P/E (TTM)
-12.8
17.5
Dividend Yield
--
52W High
$5.46
52W Low
$2.33
52W Range
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.08+0.00%
4-Quarter Trend
FCF
-$2.61M+0.00%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Net Loss Significantly Reduced Net loss attributable to common shareholders decreased to $(2.57M) USD from $(3.18M) USD for the three months ended January 31.
Operating Costs Well Managed Total operating costs fell $670K USD to $2.72M USD compared to the prior year period results.
Equity Financing Bolsters Cash Raised $1.63M USD net proceeds from an at-the-market equity offering during the current quarter period.
Liquidity Runway Confirmed Existing cash and investments estimated sufficient to fund operations for at least the next twelve months ahead.
Risk Factors
Zero Current Revenue Stream Therapeutics and vaccine programs currently generate zero revenue; profitability relies on future licensing success.
Clinical Trial Execution Risk Success hinges on positive results from ongoing lira-cel and breast cancer vaccine human clinical trials.
Stock Compensation Expense Recorded $796K USD in non-cash stock-based compensation expense across R&D and G&A functions this quarter.
Cash Position Decreased Total liquid assets declined $972K USD to $14.20M USD since the prior fiscal year end.
Outlook
Breast Vaccine Phase Two Prep Preparing to initiate Phase 2 clinical trial for breast cancer vaccine following promising Phase 1 data presentation.
CAR-T Trial Advancement Continues Continuing human clinical testing for lira-cel ovarian cancer therapy, showing well-tolerated dose escalation progress.
Potential Future Equity Raise Up to $98M USD in common stock remains available for future use under the active ATM program.
Focus on Therapeutics Development Therapeutics and vaccine development remains primary focus; legacy licensing activities expected to be minimal.
Peer Comparison
Revenue (TTM)
$106.83M
$35.95M
$35.77M
Gross Margin (Latest Quarter)
100.0%
83.6%
52.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CYBN | $413.02M | -1.7 | -61.5% | 15.9% |
| GLSI | $373.24M | -18.9 | -1042.8% | 0.0% |
| IRD | $334.48M | -5.0 | -622.0% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 26, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data